AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01501097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Renal Replacement Therapy
Description: Patients will be randomized to either arm :early HV-crrt(50ml/kg/h) or Control group
Study NCT01641432 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tonic and Phasic Attention Training
Description: The Tonic and Phasic Alertness treatment task (TAPAT) consist of two consecutive rounds of a 12-minute continuous performance task in which continually varying, rich visual (e.g., scenes, objects, faces) or auditory stimuli (tones or complex sounds) are briefly displayed and participants are required to respond via a button press when they see a non-target item (90% of trials) or withhold button-press responding when the item is a pre-determined target item (10% of trials). Presentation of the target item is non-predictive and infrequent, disallowing the development of an executive strategy. Participants simply sustain attention to the task over a prolonged period of time (tonic attention), ignoring distractions, and inhibiting the pre-potent motor response when they see a target item (phasic attention).~Following the 24 minutes of TAPAT treatment participants will undergo one additional computer-based cognitive exercise, Multiple Object Tracking (MOT), for an additional 12 minutes.
Study NCT01233726 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: T-Diet plus Diabet IR
Description: Group 1 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.
Study NCT01233726 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ISOSOURCE PROTEIN FIBRE
Description: Group 2 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.
Study NCT01641432 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Computer games chosen from a list of progressive visual/audiovisual games from the top-100 game list: sporcle.com. Training duration will be similar to that of experimental training.
Study NCT01205308 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vegetable oil based margarine with plant stanol ester enrichment
Description: 3 g plant stanols/ day
Study NCT01205308 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vegetable oil based margarine with plant stanol ester enrichment
Description: 3 g plant stanols/ day
Study NCT04679246 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participatory intervention
Description: Surveillance in compliance with the regulation of the sale of food in school buildings, according to official guidelines Training for the preparation of hygienic and healthy food for the personnel in charge of food sale Promotion of the consumption of simple water and healthy foods Reconditioning of the infrastructure for the consumption of simple water, free and healthy food, and the realization of physical activity Organization of events and support in the coordination of groups that promote physical activity at the community level Optimization of physical education classes at school sites Implementation of health promotion and care actions in the school context Development of skills in the school community for health care and generation of healthy school environments Creation and strengthening of health and nutrition committees in schools, with the participation of directors, teachers and parents to generate necessary and permanent conditions that favor healthy environments
Study NCT02874352 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: high resolution impedance manometry with Automated Impedance Manometry analysis
Study NCT03409458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT-112
Description: The RP2D of PT-112 when used in combination with avelumab has been determined during dose escalation and is being confirmed in the NSCLC dose confirmation cohort.~For the NSCLC confirmation cohort, PT-112 will be administered at a dose of 360 mg/m2 on Days 1, 8 and 15.
Study NCT03409458 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: avelumab
Description: Avelumab will be administered at a fixed dose of 800 mg on Days 1 and 15.
Study NCT03360669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sequence: Clinical/Research
Description: Participants will be assigned to a sequence of: research visit first/clinical visit second.
Study NCT03360669 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sequence: Research/Clinical
Description: Participants will be assigned to a sequence of: clinical visit first/research visit second.
Study NCT01233726 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GLUCERNA SELECT
Description: Group 3 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.
Study NCT03946267 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inverted inner limiting membrane flap technique for large full thickness macular holes
Description: The ILM, stained with IFCG or BBG, is peeled off with ILM forceps, usually beginning near the inferotemporal vascular arcade, at least 2 disk diameters from the macular hole, in a circular manner. The peeling is extended up to the edges of the macular hole, the wide ILM flap obtained reduced by trimming with the vitreous cutter, and the annular remnant of ILM hinged to the hole's edge gently inverted upside down facing the RPE. Therefore, the hole is covered with usually more layers of inverted ILM. Attention is paid to avoid insertion and filling of the hole volume with ILM.
Study NCT02632825 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal High Flow
Description: Nasal High Flow Therapy
Study NCT02111538 — intervention group
Intervention type: OTHER
Intervention: Dietary advice
Description: Standard dietary advice are provided to all patients at baseline and during the follow-up to all requiring or asking for
Study NCT02544724 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NM-IL-12
Description: Single SC administration of NM-IL-12 will be administered at least 48 hours after completion of the last chemotherapy dose of each cycle
Study NCT04686890 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spinea plane block administered preoperative open nephrectomy
Description: erector spinae plane block applied in this group before open nephrectomy
Study NCT01514175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Ibuprofen
Description: Patients will be randomized to receive 800 mg intravenous ibuprofen or 30 mg ketorolac; each of the two treatment groups will consist of 25 patients.
Study NCT01514175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Ketorolac
Description: Patients will be randomized to receive 800 mg intravenous ibuprofen or 30 mg ketorolac; each of the two treatment groups will consist of 25 patients.
Study NCT00668408 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: LTOT (oxygen therapy)
Description: Patients on LTOT will receive oxygen for at least 15 hours/day from the liquid oxygen systems at a flow rate adjusted to raise resting SaO2 between 93 and 96% and / or PaO2 between 65 and 80 mmHg every day for 3 years.
Study NCT00668408 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pharmacological therapy of COPD and CHF
Description: Optimal pharmacologic treatment will include :~* Long (LABD, salmeterol, formoterol, tiotropium) - as well as short-acting (SABD, Salbutamol, terbutaline, ipratropium)bronchodilators (beta-2 agonists, anticholinergics)~* Inhaled steroids (ICS, beclomethasone, fluticasone, budesonide always associated with LABD)~* Beta-blockers~* Diuretics~* Angiotensin-converting enzyme (ACE) inhibitors alone or in associations with diuretics~* Statins and any other treatment required for associated co-morbidities (eg insulin and/or anti-diabetic drugs, other antihypertensive, etc).~The treatment of the deseases will follow the international guidelines.
Study NCT02712242 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet Rich Fibrin
Description: Immediate and delayed bleeding, pain, epithelialization, feeding habits and sensation scores were recorded after PRF placing on palatal wounds.
Study NCT02712242 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Butyl cyanoacrylate
Description: Immediate and delayed bleeding, pain, epithelialization, feeding habits and sensation scores were recorded after Butyl Cyanoacrylate application on palatal wounds.
Study NCT02712242 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wet gauze
Description: Immediate and delayed bleeding, pain, epithelialization, feeding habits and sensation scores were recorded after wet gauze pressure on palatal wounds.
Study NCT05033457 — intervention group
Intervention type: PROCEDURE
Intervention: unilateral biportal endoscopy technique or percutaneous endoscopic transforaminal discectomy
Description: Treatment of lumbar intervertebral disc herniation with unilateral biportal endoscopy technique in unilateral biportal endoscopy technique group.Treatment of lumbar intervertebral disc herniation with percutaneous endoscopic transforaminal discectomy in percutaneous endoscopic transforaminal discectomy group.
Study NCT01101555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subcutanious administration
Description: drug will be administered subcutaneously in varying amounts over a verying time period according to details stated in the 'arms' section
Study NCT04686890 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intravenous analgesic ( 1 mg/kg tramadol + non-steroid antiinflamatuar paracetamol )drug + 10 mg.kg
Description: intarvenous analgesic administered in this group for analgesia end of the open nephrectomy
Study NCT01101555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be given to one member of each cohort.
Study NCT03790969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 26 gauge needle
Description: smaller gauge needle
Study NCT03790969 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 23 gauge needle
Description: control group
Study NCT01783938 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT02991612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Patients receive Rifaximin 400mg bid for 2 months
Study NCT02271490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acrosome Reaction induction
Study NCT02271490 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: capacitation in incubation medium prior to ICSI
Study NCT00789204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global Postural Re-education
Description: The treatment in Global Postural Re-education is a global approach that seeks to identify the biomechanical cause of the problem also in other parts of the body and involves actively the patient in the postural change. Using principles like causality, globality and individuality, the treatment consists of the use for one hour of progressive active stretching posture for specific muscular chain that are shortened. Every posture is maintained for 20 minutes with controlled breathing and the use of manual traction
Study NCT01783938 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT03753477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1351(FDC Amlodipine/Olmesartan/Rosuvastatin)
Description: DWJ1351(FDC Amlodipine/Olmesartan/Rosuvastatin) X 1 tablet followed by Sevikar(Amlodipine/Olmesartan) X 1 tablet and Crestor(Rosuvastatin) X 1 tablet (after washout period)
Study NCT03753477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevikar and Crestor
Description: Sevikar(Amlodipine/Olmesartan) X 1 tablet and Crestor(Rosuvastatin) X 1 tablet followed by FDC Amlodipine/Olmesartan/Rosuvastatin X 1 tablet (after washout period)
Study NCT04663217 — intervention group
Intervention type: OTHER
Intervention: Exercise
Description: After placement of the right heart catheter patients will undergo an exercise challenge in semi-supine position until exhaustion
Study NCT03812250 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP assisted trans-papillary drainage for malignant biliary obstruction
Description: ERCP assisted trans-papillary drainage for malignant biliary obstruction
Study NCT03812250 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-guide biliary drainage for malignant biliary obstruction
Description: EUS-guide biliary drainage for malignant biliary obstruction
Study NCT01978574 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intellectual Enrichment daily activities
Description: A daily program of intellectually enriching, iPad/tablet-based activities: games, reading/writing, hobby activities, or a documentary video (control).
Study NCT01978574 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intellectual Enrichment documentary videos
Description: Participants watch daily documentary videos.
Study NCT01522027 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous tracheostomy
Description: Twenty ICU patients will receive percutaneous tracheostomy via insertion of a needle/catheter connected to a nerve stimulator.
Study NCT01713140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1 strength training set performed until contraction failure
Description: Electromyographic (EMG) activity of the vastus medialis (VM), vastus lateralis (VL), semitendinosus (ST) and biceps femoris (BF) muscles will be recorded during knee extensions performed in a knee extension machine in a single set performed until contraction failure. The relative loading will be 10 repetition maximum (RM). The absolute load (kilograms) corresponding to 10 RM is defined a minimum of 3 days before the day where the EMG-data are recorded. Range of motion and time under tension for each repetition will be controlled for.
Study NCT06376227 — intervention group
Intervention type: PROCEDURE
Intervention: with or without Left Colic Artery Preservation
Description: low ligation (LL) which with preservation of LCA and high ligation (HL) which without preservation of LCA
Study NCT00789204 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Exercise Training
Description: The exercise programme included passive lumbar flexion, pelvic tilt, strengthening of flexor muscles, strengthening of extensor muscles, spine mobilization and stretching exercises.
Study NCT01613105 — intervention group
Intervention type: DRUG
Intervention: Acarbose (Precose/Glucobay, BAYG5421)
Description: Oral Glucobay 25 titrated to Glucobay 50 upto three times a day with meals or as per investigators descretion.
Study NCT03435900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of fosfomycin, metronidazole and rhGM-CSF (administered together intraperitoneally) and three days of antibiotics p.o.
Description: All drugs will be administered together intraperitoneally at the end of the surgery after the appendix has been removed. Hereafter, the intervention group will receive three days of orally administered antibiotics: 500 mg amoxicillin combined with 125 mg clavulanic acid and 500 mg metronidazole. These doses will be administered three times daily.
Study NCT03435900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard antibiotics intravenously
Description: 4 g piperacillin/500 mg tazobactam and 1 g metronidazole administered intravenously during surgery followed by 4 g piperacillin/500 mg tazobactam and 500 mg metronidazole administered intravenously three times daily for three days.
Study NCT03832231 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shear Wave Elastography
Description: Ultrasound technology to assess tissue stiffness
Study NCT03261869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold application
Study NCT03478787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: Subcutaneous (SC) injection
Study NCT03478787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: secukinumab
Description: Subcutaneous (SC) injection
Study NCT01121575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02341066
Description: Arm 1: The starting dose will be 200 mg by mouth, twice a day of PF 02341066 in tablet form The dose of each drug in the combination \[PF-02341066 and PF-00299804\] will be escalated or de-escalated until the maximum tolerated combined dose is reached. Patients will then be treated with the maximum tolerated combined dose.
Study NCT01121575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00299804
Description: Arm 1: The starting dose will be 30 mg by mouth once a day of PF-0029804 in tablet form. The dose of each drug in the combination \[PF-02341066 and PF-00299804\] will be escalated or de-escalated until the maximum tolerated combined dose is reached. Patients will then be treated with the maximum tolerated combined dose.
Study NCT01121575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02341066
Description: Arm 2: With progressive disease the maximum tolerated combined dose of PF-02341066 (given by mouth twice a day in tablet form) and PF-00299804 (given by mouth once a day in tablet form).
Study NCT01121575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00299804
Description: Arm 2: The dose of 45 mg by mouth once a day of PF-00299804 in tablet form until progressive disease and then the maximum tolerated combined dose of PF-02341066 (given by mouth twice a day in tablet form) and PF-00299804 (given by mouth once a day in tablet form).
Study NCT00804479 — intervention group
Intervention type: OTHER
Intervention: No intervention.
Study NCT03315559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-GSK2269557 IV infusion
Description: The \[14C\]-GSK2269557 solution will be available in dosing strength of 10 µg, administered as single dose IV infusion over 15 minutes. It will be prepared by dissolving a hemisuccinate salt (GSK2269557T) in normal saline.
Study NCT03315559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557 via DPI
Description: GSK2269557 DPI will be available with dosing strength of 1000 µg, administered as oral inhalation intended to inhale twice. It will be prepared by blending GSK2269557 hemisuccinate salt (GSK2269557H) with lactose and magnesium stearate.
Study NCT04500015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INH
Description: 3 vaginal tablet of isonicotinic acid hydrazide self-inserted by the patient 12 hours before IUD insertion.
Study NCT04500015 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: 3 tablet of placebo self-inserted by the patient 12 hours before IUD insertion.
Study NCT03315559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-GSK2269557 oral solution
Description: The \[14C\]-GSK2269557 solution will be available with dosing strength of 800 µg, administered as single dose orally. It will be prepared by dissolving \[14C\]-GSK2269557 hemisuccinate salt (GSK2269557T) in water.
Study NCT01610388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500mg IV GSK1322322/placebo
Description: 500mg IV
Study NCT01610388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1000mg oral GSK1322322/placebo
Description: 1000mg oral
Study NCT01610388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1000mg IV GSK1322322/placebo
Description: 1000mg IV
Study NCT01610388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1500mg oral GSK1322322/placebo dose
Description: 1500mg oral
Study NCT01610388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1500mg IV GSK1322322/placebo
Description: 1500mg IV
Study NCT01610388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2000mg IV GSK1322322J/placebo
Description: 2000mg IV
Study NCT00393458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
Study NCT00393458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Formoterol was supplied in powder-filled capsules with the manufacturer's proprietary inhalation device (Aerolizer®).
Study NCT00393458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to indacaterol
Description: Placebo to indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
Study NCT01610388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3000mg IV GSK1322322J/placebo
Description: 3000mg IV
Study NCT01610388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1000mg IV GSK1322322J/placebo
Description: 1000mg IV
Study NCT03377127 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacy Managed Diabetes Clinic (PMDC)
Description: The PMDC visit encounters will focus on patient identified goals for the management of their diabetes. Initial visit in the PMDC will be 60-90 minutes with follow up visits lasting 30-45 minutes.
Study NCT03377127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC)
Description: Standard of care will be delivered at the physician discretion per the current American Diabetes Association recommendations
Study NCT03377127 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Description: Standard of care will be delivered at the physician discretion per the current American Diabetes Association recommendations
Study NCT02413346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarecycline
Description: Administered based on participant's body weight.
Study NCT02595554 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent chemoirradiation
Description: External beam radiation therapy (EBRT) with concurrent weekly platinum chemotherapy followed by brachytherapy